Orasis Pharmaceuticals

Company Overview

Snapshot

Founded in September 2015, Orasis Pharmaceuticals operates with 51–200 employees. The company has raised a total of $121 million across 5 funding rounds from 12 investors. In October 2023, Orasis Pharmaceuticals announced the FDA approval of QLOSI™ (pilocarpine hydrochloride ophthalmic solution) 0.4% for the treatment of presbyopia.

Business overview

Orasis Pharmaceuticals is an ophthalmic pharmaceutical company focused on developing treatments for presbyopia, the gradual loss of the eye’s ability to focus on near objects. Its core product is QLOSI™ (pilocarpine HCl ophthalmic solution) 0.4%, an FDA-approved prescription eye drop designed as an alternative to reading glasses. The company operates within the Health Tech & Life Sciences sector, specifically targeting the pharmaceutical and medical biotechnology markets with its drug discovery and development efforts.

Strategic signal

In October 2024, Orasis Pharmaceuticals completed a $78 million financing round, led by. This significant capital infusion signals strong investor confidence in the company's commercialization strategy and its potential to disrupt the presbyopia treatment market, moving from clinical development to market entry.

Company Intelligence Q&A

What is the primary product developed by Orasis Pharmaceuticals?

Orasis Pharmaceuticals has developed QLOSI™ (pilocarpine HCl ophthalmic solution) 0.4%, an FDA-approved prescription eye drop for the treatment of presbyopia, offering an alternative to reading glasses.

When did Orasis Pharmaceuticals receive FDA approval for its lead product?

Orasis Pharmaceuticals announced the FDA approval of QLOSI™ (pilocarpine hydrochloride ophthalmic solution) 0.4% for the treatment of presbyopia in October 2023.

What was the purpose of the October 2024 financing round?

In October 2024, Orasis Pharmaceuticals completed a $78 million financing round, led by.

Did Orasis Pharmaceuticals enter into any recent commercialization agreements?

In October 2024, Orasis announced a licensing agreement with Optus Pharmaceuticals for the commercialization of Qlosi eye drops in Korea.

When did Orasis Pharmaceuticals submit its New Drug Application for CSF-1?

Orasis Pharmaceuticals submitted its New Drug Application for the investigational novel eye drop candidate, CSF-1, for the treatment of presbyopia in January 2023.